Are we ready for therapeutic drug monitoring of biologic therapeutics?
1 Jan van Breemen Research Institute/Reade, dr Jan van Breemenstraat 2, 1056 AB Amsterdam, The Netherlands
2 Department of Rheumatology, VU University Medical Centre, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
Arthritis Research & Therapy 2011, 13:120 doi:10.1186/ar3395
See related research by Ducourau et al., http://arthritis-research.com/content/13/3/R105Published: 2 August 2011
In the previous issue of Arthritis Research & Therapy, Ducourau and colleagues report that they retrospectively detected anti-infliximab antibodies in 21% of patients with rheumatic diseases. Patients with anti-infliximab antibodies had lower serum drug concentrations. These findings contribute to the existing evidence of immunogenicity of biologicals and its clinical relevance. We argue for therapeutic drug monitoring to optimize treatment response.